Summary:
- Mustang Bio, Inc. (MBIO, Financial) retains Nasdaq listing by meeting key compliance metrics.
- Wall Street analysts offer a bullish outlook with price targets significantly above current levels.
- The stock holds an "Outperform" consensus, reflecting positive sentiment from brokerage firms.
Mustang Bio, Inc. (MBIO) has successfully met Nasdaq's minimum stockholders' equity and bid price requirements, ensuring its continued presence on the Nasdaq Capital Market. This accomplishment underscores the company's strategic progress in developing groundbreaking cell therapies aimed at cancer treatment.
Wall Street Analysts Forecast
According to the insights provided by one analyst covering Mustang Bio, Inc. (MBIO, Financial), the average one-year price target is set at $10.00. This target ranges from a high of $10.00 to a low of $10.00, representing a substantial upside potential of 652.22% from the current trade price of $1.33. For more in-depth analysis and data, visit the Mustang Bio Inc (MBIO) Forecast page.
The consensus from one brokerage firm positions Mustang Bio Inc. at an average brokerage recommendation of 2.0, signifying an "Outperform" status. This rating is part of a scale from 1 (Strong Buy) to 5 (Sell), indicating a strong endorsement of the company's prospects.
